Reported results
- Revenue from continuing operations was $567.8 million, up 0.2% compared to the prior year period, and up 3.0% on a pro forma adjusted constant currency basis.
- GAAP diluted EPS from continuing operations was $1.30, compared to $(1.32) in the prior year period.
- Adjusted diluted EPS from continuing operations was $2.63, compared to $1.89 in the prior year period.
- The Company repurchased $350 million in common stock through an accelerated share repurchase program and open-market transactions between July 1, 2026 and the date of the release.
Guidance
- Reducing GAAP revenue growth guidance range to 13.2% to 14.2% for full year 2026.
- Maintaining pro forma adjusted constant currency revenue growth guidance range of 3.5% to 4.5% for full year 2026.
- Increasing GAAP EPS from continuing operations guidance range to $2.84 to $3.09 for full year 2026.
- Increasing Adjusted diluted EPS from continuing operations guidance range to $7.50 to $7.75 for full year 2026.
Notes
During the third quarter of 2026, the Company changed its reportable segments to a global business unit presentation (Vascular, Interventional, and Surgical), and all prior comparative periods have been restated to reflect these changes.
Price and volatility reaction
The stock moved +1.5% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -20.0 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 149.87 | 2026-11-04 |
| Close after release | 152.15 | 2026-11-05 |
| Realised move | +1.5% | close to close |
| 30d ATM IV change | -20.0 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
